Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201205111 Principal Investigator: Fehniger, Todd
Title: A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients with High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
Phase: I/II Disease Site: Myeloid and Monocytic Leukemia
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
This study is being done to evaluate a drug called CNDO-109 Activated Allogeneic Natural Killer Cells and how patients with Acute Myeloid Leukemia (AML) respond when given this therapy.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)